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Abstract
Background: The Swiss Federal Office of Public Health has recommended vaccination against human
papillomavirus (HPV) to prevent cervical cancer since 2008. To establish monitoring of the future public health
impact of vaccination, baseline population-based data are required. The objectives of this study were to examine
the distribution of oncogenic HPV genotypes in biopsies with cervical intraepithelial neoplasia stage 3 or more
severe lesions (CIN3+) at the beginning of HPV vaccination programmes and to compare sociodemographic and
behavioural factors of women with CIN3+ with women in the Swiss general population.
Methods: We conducted a retrospective and prospective cross-sectional study with women diagnosed with CIN3+
in Switzerland. Ten pathology institutes from six cantons and three language regions participated. We conducted
HPV typing on formaldehyde fixed-paraffin embedded specimens from 2014 and 2015. Women enrolled in 2015
were asked to complete a questionnaire. We described frequencies of HPV types. We also compared demographic
characteristics and socioeconomic status in the CIN3 + plus group with the Swiss National Cohort in 2014 and
compared risk factors for HPV infection with the Swiss Health Survey in 2012.
Results: We included 768 biopsies from 767 women. Four hundred and seventy-five (61.8%) biopsies were positive
for HPV 16 and/or 18, 687 (89.5%) were positive for oncogenic HPV genotypes 16, 18, 31, 33, 45, 52, and/or 58 and
five (0.7%) were HPV negative. Twenty-eight (10.3%) of the 273 women who completed the patient questionnaire
reported having received at least one dose of an HPV vaccine. When compared with Swiss women in the six study
cantons, fewer women in the CIN3+ plus study group were of Swiss nationality, more were born abroad and more
were single. The study group also had a higher proportion of women with ≥2 partners in the last year, current
smokers and was younger at age of first sexual intercourse.
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Conclusions: Introduction of the nonavalent vaccine could cover approximately 90% of CIN3+ lesions in Swiss
women compared with around 60% with the quadrivalent vaccine. Surveillance of HPV genotype distribution in
CIN3+, together with information about vaccination and CIN3+ incidence will allow monitoring of the public health
impact of vaccination programmes.
Trial Registration: ClinicalTrials.gov, NCT02323997. Registered 24 December 2014.
Keywords: HPV, Human papillomavirus, Vaccines, Cervical cancer, Cervical dysplasia, Cervical intraepithelial
neoplasia
Background
Human papillomavirus (HPV) vaccines provide strong
protection against persistent HPV infections. Most HPV
infections of the cervix are cleared by the immune system,
but persistent HPV infections with some genotypes cause
cervical cancer [1]. Of more than 100 identified HPV ge-
notypes, the International Agency for Cancer Research
(IARC) classifies 12 HPV genotypes (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58 and 59) as causal agents of cervical can-
cer and another eight (26, 53, 66, 67, 68, 70, 73 and 82) as
probable or possible causes of cervical cancer [2]. In a
meta-analysis of studies from 61 countries worldwide,
HPV types 16 and 18 were found in 70% of all invasive
cervical cancer and 52% of high-grade squamous
intraepithelial specimens [3]. Three types of HPV vaccines
are licensed worldwide. Bivalent vaccines contain
non-infectious virus-like particles (VLPs) of oncogenic
HPV genotypes 16 and 18 [4, 5], quadrivalent vaccines
contain VLPs of HPV 16 and 18 and HPV 6 and 11, which
cause genital warts, and a nonavalent vaccine contains
VLPs of HPV 16, 18, 31, 33, 45, 52 and 58 and types 6 and
11 [6]. All three vaccines have been approved for use in
the European Union since 2015 [7] and the United States
of America since 2014 [8] but, as of August 2018, only bi-
valent and quadrivalent vaccines are available in
Switzerland. HPV vaccine has been introduced into vac-
cination programmes in 73 countries [9].
The real-world impact of HPV vaccination pro-
grammes on morbidity and mortality can only be evalu-
ated by post-licensure comparison of HPV-associated
outcomes before and after HPV vaccine introduction.
The World Health Organization (WHO), European
Centre for Disease Prevention and Control (ECDC) and
Australian government [10] recommend monitoring of
HPV infection prevalence, incidence of genital warts, in-
cidence of pre-cancerous cervical intraepithelial neopla-
sia (CIN), and invasive cervical cancer incidence and
mortality [11–13]. Cervical cancer takes up to 20 years
to develop [14] and is rare in high income countries, so
specimens collected over many years are needed to ob-
tain sufficient precision to estimate HPV-type specific
prevalence [10]. In Switzerland, descriptive data are lim-
ited. To assess HPV type distribution over a shorter time
frame, a pragmatic disease outcome could include severe
CIN (grade 3) or adenocarcinoma in situ, which usually
develop seven to 15 years after HPV infection [15]; to-
gether with invasive cancer these conditions are referred
to as CIN3+ [16].
We designed the CIN3+ plus study to provide infor-
mation about the feasibility of a future surveillance sys-
tem and the impact of HPV vaccination in Switzerland.
In Switzerland, HPV vaccination programmes for young
girls and women began in 2008, organised by health au-
thorities in the 26 cantons (states) and targeting 11 to
14 year old girls, with recommendations for catch up
vaccination for women up to 26 years of age. The Swiss
Federal Office of Public Health conducted a national
survey in 2014 with 2363 women aged 18–24 years and
found that 41.3% (95% CI 36.4–46.3) reported receiving
three HPV vaccine doses, 4.7% (95 CI 3.3–6-6) two
doses and 5.4% (95% CI 3.6–8.0) one dose [17]. Cantonal
cancer registries record incidence and mortality of cer-
vical cancers, but not all record CIN3 and none records
the HPV type [18]. The primary objective of this study
was to determine the baseline distribution of oncogenic
HPV genotypes in women diagnosed with CIN3+ in
women living in Switzerland at the start of the cantonal
vaccination programmes. Secondary objectives were to
compare sociodemographic and epidemiological charac-
teristics between women with CIN3+ and women in the
general Swiss population.
Methods
The CIN3+ plus study period was January 2014 to De-
cember 2015. We conducted a cross-sectional study in
the year 2015, consisting of retrospectively analysed
formaldehyde-fixed paraffin-embedded (FFPE) speci-
mens from 2014 and samples and data from women en-
rolled prospectively during 2015. We assumed that the
majority of women diagnosed with CIN3+ during the
study period would not have received HPV vaccination,
either because the target age group for vaccination
would be too young to have developed CIN3+, or be-
cause the uptake of HPV vaccination amongst older
women was too low to have had an impact on CIN3+ in-
cidence. Ten pathology institutes from six cantons
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(Basel-City, Basel-Land, Geneva, Lucerne, Ticino and
Zurich) and three language regions (German, French
and Italian) participated in the study. Three institutes
were based at publicly funded university hospitals, three
were publicly funded non-academic institutes and four
were private institutes. To select specimens collected in
2014, we provided the institutes with lists of random
numbers, which they used to label biopsy specimens
with a diagnosis of CIN3+ from women living in any of
the participating cantons. We calculated the number of
biopsies for each institute, based on the proportion of
the total number of CIN3+ cases that each laboratory di-
agnosed in 2014. We used open access software (Open-
Epi, version 3.1) to generate the random number lists. If
there was not enough biopsy material for testing, we
asked institutes to use the next biopsy with CIN3+. We
enrolled women prospectively during 2015. We sent in-
formation about the CIN3+ plus study to gynaecologists
of women who were diagnosed with CIN3+ and who
met the inclusion criteria and asked them to obtain writ-
ten informed consent from the woman. Inclusion criteria
were: ≥18 years of age, living in one of the participating
cantons and literate in German, French, Italian or Eng-
lish. We published a short description of the study
methods and basic results in the bulletin of the Swiss
Federal Office of Public Health [19].
HPV genotyping
We conducted HPV typing on specimens prepared from
stored FFPE blocks from cervical biopsies, cone biopsies,
endometrial curettage specimens and/or hysterectomies.
If more than one biopsy was available for a patient, we
analysed the most recent and/or best preserved biopsy.
Each institute conducted HPV typing according to their
routine practice and standard operating procedures for
deparaffinisation, tissue digestion and DNA extraction. All
institutes used their routine nucleic acid amplification test,
all of which included targets for the IARC-defined
high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58 and 59 and a variety of other HPV genotypes (Add-
itional file 1: Table S1). For specimens that tested negative
for HPV, two aliquots of the purified DNA were sent to
the WHO HPV Laboratory Network Reference Labora-
tory in Stockholm, Sweden [20] and tested using
MGP-PCR followed by Luminex and B-globin real-time
PCR. Their laboratory methods are described in a separate
publication [21]. In addition, all participating laboratories
were requested to participate in the WHO HPV Labora-
tory Network proficiency panel testing, a quality assurance
system for HPV genotyping [20].
Sociodemographic and behavioural data
We collected basic demographic data and clinical and
histopathological diagnosis for all patients. Prospectively
enrolled patients from 2015 who gave written informed
consent were asked to complete a written questionnaire
that asked for additional information, including HPV
vaccination status, sociodemographic characteristics,
smoking history and sexual behaviour. We entered all
data into a piloted Research Electronic Data Capture
form (REDCap™ Software, Vanderbilt University, Nash-
ville, Tennessee, USA). We calculated a proxy of socio-
economic position (SEP) for all patients with a valid
address using the Swiss neighbourhood index of SEP
(Swiss-SEP) [22]. The Swiss-SEP is a small area-based
measure based on median rent per square metre, pro-
portion of households headed by a person with primary
education or less, proportion of households headed by a
person in a manual or unskilled occupation and the
mean number of persons per room [22]. The Swiss-SEP
index was developed with 2000 Swiss census data and
has a range from zero (lowest SEP) to 100 (highest SEP),
with a median of 63.32. When calculating the Swiss-SEP
for our study, we used the closest residential house from
the 2000 census to the geographic coordinate of interest.
For comparison, we obtained demographic data from
women in the general Swiss population from the Swiss
National Cohort (SNC) [23] and behavioural data from
the Swiss Health Survey (SHS) [24]. The SNC is a
census-based cohort of basic individual-level data (e.g.
canton, age, sex, etc.), which includes the entire Swiss
population. Additional variables (e.g. education level, oc-
cupation) were collected with a structured written ques-
tionnaire, which was completed by a random subset of
the Swiss population in 2014. The SHS is a written ques-
tionnaire and telephone interview conducted with ran-
domly selected individuals living in Switzerland in 2012.
Women ≥18 years of age living in one of the participat-
ing cantons were included from the SNC and SHS for
analysis. An additional inclusion criterion for the SHS
was that both the telephone interview and written ques-
tionnaire were completed.
Sample size and statistical analysis
We planned a sample size of approximately 900 samples.
The inclusion of samples from 2014 allowed us to in-
crease the precision of estimates of type-specific HPV
prevalence. The sample size was based on the number of
CIN3+ cases diagnosed per year (approximately 760 per
year in the participating cantons), a prevalence of 70%
for HPV 16/18 [25] and an estimated response rate of
75%. We planned to test 250–500 retrospective biopsies
from 2014 and 250–500 prospective biopsies from 2015.
We performed analyses using statistical software
(STATA, version 14.0, Statcorp, College Station, Texas
USA). We applied age-adjusted weights to the SNC and
SHS datasets to compare characteristics with women in
the CIN3 + plus study group. We used chi-squared tests
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to compare nominal and ordinal variables and linear re-
gression to compare continuous variables.
Results
We included a total of 768 biopsies from 767 women in
the study (Fig. 1). For 11 women, two participating la-
boratories received a biopsy. Biopsies from the same
patient with the same HPV results (n = 10) were consid-
ered only once in the analysis. One woman had two bi-
opsies with different HPV results and both were
included. From 2014, we retrospectively included 474 bi-
opsies from 465 women. During 2015, we contacted the
gynaecologists of 795 women diagnosed with CIN3+.
Three hundred and four (38.2%) women gave informed
consent, 20 declined participation and we received no
reply from 471. In addition, 273 patients in 2015 com-
pleted and returned a patient questionnaire (Fig. 1).
The mean age of women included was 35.5 years (stand-
ard deviation, SD ±10.6, range 17–81). Seven-hundred
and two of 768 (91.4%) biopsies were diagnosed with
CIN3, 33 (4.3%) with adenocarcinoma in situ, 24 (3.1%)
with squamous cell carcinoma and nine (1.2%) with
adenocarcinoma. Characteristics of retrospective and pro-
spective patients were similar (Additional file 1: Table S2).
The diagnoses were based on the following samples: 424
(54.2%) cone biopsies, 292 (37.3%) punch biopsies, 24
(3.1%) curettage biopsies, 16 (2.0%) biopsies from hyster-
ectomies and 27 (3.5%) biopsies from other types of pro-
cedures. Six of 273 (2.2%) of the women who completed
the patient questionnaire reported that they have been di-
agnosed as HIV-positive and 9 (3.3%) women did not an-
swer the question. Twenty-eight of 273 (10.3%) women
who completed the patient questionnaire reported having
received at least one dose of an HPV vaccine. Only one of
28 vaccinated women reported not having had sexual
intercourse before receiving a single dose of quadrivalent
vaccine. She had CIN3+ with HPV type 52. Twelve of the
28 women were > 26 years of age at the time of reported
vaccination.
HPV genotypes
Four hundred and seventy-five (61.8%; 95% CI 58.3–65.3)
of the 768 biopsies were positive for HPV 16 only, HPV
18 only or both HPV 16 and 18. Four hundred and thirty
five (56.6%; 95% CI 53.1–60.2) biopsies were positive for
HPV 16 alone and 50 (6.5%; 95% CI 4.9–8.5) were positive
for HPV 18 alone. One or more of the oncogenic HPV ge-
notypes contained in the nonavalent HPV vaccine were
present in 687 (89.5%; 95% CI 87.1–91.5) of the biopsies.
One or more of the HPV genotypes classified as oncogenic
Fig. 1 Study flow chart. Originally published in Swiss Federal Office of Public Health Bulletin (reference 19).a 11 patients were included in the
study twice by different laboratories.b 10 biopsies were excluded because they were from the same patient with the same HPV result
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by IARC were present in 727 (94.7%; 95% CI 92.8–96.1) of
the biopsies. The HPV distribution for retrospectively and
prospectively included biopsies was similar (Table 1).
Multiple HPV genotypes were detected in 95
(12.4%; 95% CI 10.1–14.9) of the tested biopsies. The
ranking of the ten most frequent HPV genotypes in
our samples was: HPV 16, 56.6%; HPV 31, 12.5%;
HPV 33, 7.2%; HPV 18, 6.5%; HPV 52, 5.7%; HPV 58,
4.3%; HPV 51, 3.4%; HPV 35, 2.5%; HPV 45, 2.0%;
HPV 42, 1.3% (Additional file 1: Table S3). The fre-
quencies of HPV 16 and/or 18, HPV oncogenic geno-
types contained in the nonavalent vaccine or HPV
genotypes classified as oncogenic by IARC did not
differ according to Swiss-SEP quintile level (p = 0.167).
HPV 16 only, HPV 18 only or both HPV 16 and 18
were present in 427/702 (60.8, 95% CI 57.1–64.5) of the
biopsies diagnosed as CIN3 and 24/33 (72.7, 95% CI
54.5–86.7) of invasive cervical cancers (adenocarcinoma
and squamous cell carcinoma). At least one of the HPV
genotypes contained in the nonavalent vaccine was de-
tected in 626/702 (89.2, 95% CI 86.6–91.4) of the
biopsies diagnosed as CIN3 and 32/33 (97.0, 95% CI
84.2–99.9) of invasive cervical cancers (Table 2). The fre-
quency of individual HPV genotypes according to histo-
logical diagnosis is shown in Additional file 1: Table S4.
HPV negative and non-evaluable biopsies
On initial analysis, 729/768 (94.9%) samples were positive
for HPV, 20 (2.6%) were negative for HPV and 19 (2.5%)
were non-evaluable owing to the presence of PCR inhibi-
tors or lack of material (Additional file 1: Figure S1). The
WHO Global HPV Reference Laboratory in Stockholm,
Sweden reanalysed 17 HPV negative samples and
one non-evaluable biopsy with adequate material. Fifteen
out of the 17 samples that were negative on original ana-
lysis were found to be positive for HPV. Two samples
were confirmed as negative for HPV. Three of the nega-
tive samples were not confirmed because no material was
available for retesting. One of the non-evaluable samples
retested was found to be positive for HPV types 16, 18
and 51. In summary, 5/768 (0.7%; 95% CI 0.2–1.5) of the
analysed samples were considered negative for HPV
(Table 2) and 18/768 (2.3%; 95% CI 1.4–3.7)
non-evaluable after confirmatory testing (Additional file 1:
Figure S1).
Comparison of the CIN3 + plus study group with women
in the general population
We obtained a Swiss-SEP index for 748/767 (97.5%)
of the enrolled women. The comparison of the CIN3
+ plus study group with the SNC (n = 54,769) showed
that both groups had the same Swiss-SEP index
(mean = 64.6; p = 0.999). Fewer women in the CIN3+
plus study group were of Swiss nationality (63.2% vs.
69.6%; p = 0.024), more were born abroad (51.0% vs.
40.0%; p = 0.001) and more were single (48.9% vs.
45.5%; p < 0.001). Differences in proportions were
also observed between the groups in regards to the
canton of residence (p < 0.001) and highest education
level obtained (p = 0.004) (Table 3).
Some factors associated with HPV infection dif-
fered between the CIN3 + plus study group and SHS
(n = 3537) (Table 4). Women in the CIN3+ plus study
were more likely to have reported ≥2 sexual partners in
the last 12months (15.4% vs. 6.8%; p = 0.001) and reported
younger age at first sex (17.5 vs. 18.1 years; p = 0.005).
Women in the CIN3+ plus study were more likely to re-
port that they were smokers (38.5% vs. 25.5%; p < 0.001).
The proportion of women who reported hormonal
contraception use in the last 12 months was 35.5% in
the CIN3+ plus group and 41.7% in the SHS group
(p = 0.072). A higher proportion of women in the
CIN3+ plus study group reported ever having a cervical
cancer screening test (89.0% vs. 81.5%; p = 0.002).
Discussion
In this cross-sectional study of women with CIN3+ in
2014 and 2015, HPV genotypes 16 and/or 18 were de-
tected in 61.8% of the biopsies analysed and HPV geno-
types 16, 18, 31, 33, 45, 52 and/or 58 contained in the
nonavalent vaccine, were detected in 89.5% of biopsies.
84.9% contained a single HPV type, 12.4% contained
multiple HPV types and only 0.7% of samples had no
Table 1 Oncogenic HPV genotypes present in CIN3 + plus study biopsiesa
Retrospective (2014) Prospective (2015) All p-value
Biopsies, n = 465 Biopsies, n = 303 N = 768
HPV types, n, % (95% CI) HPV types, n, % (95% CI)
HPV 16 and/ or 18 281, 60.4 (55.8–64.9) 194, 64.0 (58.3–69.4) 475, 61.8 (58.3–65.3) 0.316
Oncogenic HPV genotypes in nonavalent vaccineb 417, 89.7 (86.5–92.3) 270, 89.1 (85.0–92.4) 687, 89.5 (87.1–91.5) 0.802
All other high-risk HPV genotypesc 45, 9.7 (7.1–12.7) 21, 6.9 (4.3–10.4) 66, 8.6 (6.7–10.8) 0.184
Abbreviations: CI confidence interval
aMultiple HPV genotypes may be present in one biopsy so the total number of HPV types is higher than the number of biopsies
bOne more of the following HPV genotypes present: 16, 18, 31, 33, 45, 52, 58
cOne or more of the following HPV genotypes present: 35, 39, 51, 56, 59
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HPV detected. Only 10.3% of the women who com-
pleted a patient questionnaire reported receiving a
HPV vaccine. Socioeconomic position was the same
for women in the CIN3 + plus study group and the
SNC. The CIN3+ plus study population consisted of
more single, non-Swiss women born abroad when com-
pared to the Swiss general population. The CIN3+ plus
study group had a higher proportion of women with ≥2
partners in the last 12months, current smokers and were
younger at the age of first sexual intercourse when com-
pared with the SHS.
Strengths and weaknesses
A strength of our study for public health surveillance of
vaccine impact is that we analysed whole tissue biopsies
with CIN3+ rather than cytological samples from cer-
vical smears. This outcome is closer to the clinical end-
point of interest, cervical cancer, than HPV infection or
mild dysplasia, which often regress. Additional strengths
include the enrolment of women from all three language
regions in Switzerland, collection of demographic and
behavioural data that allowed a comparison with women
in the general population and the inclusion of public,
private and university laboratories. Although we only
conducted the CIN3 + plus study in six of the 26 Swiss
cantons, these cantons include 38.4% of the entire Swiss
female population (1612992) [26]. An important limita-
tion of this study is that participating laboratories did
not use a standardised test for HPV detection, which
could have affected our results. Some HPV genotype
testing methods have been shown to produce compar-
able results in FFPE [27, 28]. However, for many assays,
especially laboratory developed tests, formal compari-
sons are lacking and only three out of the eight testing
laboratories participated in the WHO HPV Laboratory
Network proficiency panel testing programme. Variabil-
ity in test technology is expected in decentralised public
health surveillance systems. To ensure that we did not
miss HPV infections in samples that tested negative, an
independent laboratory retested all negative specimens
with enough available material; the final proportion of
specimens with no HPV detected was very low. Another
limitation was the apparently low percentage of eligible
women who completed the questionnaire. We do not
believe that non-participation resulted in bias because
very few women specifically declined participation, so it
is likely that gynaecologists simply did not have time to
explain the study and obtain consent. If a surveillance
system were introduced, additional information would
probably be limited to HPV vaccination status and in-
formed consent would not be required.
Comparison with other studies
We found few reports of studies conducted to provide
baseline data for the monitoring of HPV vaccination im-
pact. Dobec et al. examined specimens from 202 women
in Switzerland with cytological abnormalities in 2007
[29]. High risk HPV types were found in 98 of 136
women with low-grade squamous intraepithelial lesions
(72.1%; 95% CI 64.0–78.9) and 32 of 33 with high-grade
squamous intraepithelial lesions identified by cytology
(97.0%; 95% CI 83.4–99.9). There were no cases of inva-
sive carcinoma in that study. One study in Australia ex-
amined the distribution of HPV genotypes in specimens
Table 2 HPV genotype distribution according to histological diagnosis
HPV genotypea CIN3 Adenocarcinoma in situ Squamous cell
carcinoma
Adenocarcinoma Invasive cancers
(Squamous cell and
adenocarcinoma)
N = 702 N = 33 N = 24 N = 9 N = 33
n, % (95 CI) n, %, (95 CIb) n, %, (95 CIb) n, %, (95 CIb) n, %, (95 CIb)
HPV 16 and/or 18 427, 60.8 (57.1–64.5) 24, 72.7 (54.5–86.7) 16, 66.7 (44.7–84.4) 8, 88.9 (51.8–99.7) 24, 72.7 (54.5–86.7)
HVP 16 positive 398, 56.7 (52.9–60.4) 18, 54.5 (36.4–71.9) 14, 58.3 (36.6–77.9) 5, 55.6 (21.2–86.3) 19, 57.6 (39.2–74.5)
HPV 18 positive 36, 5.1 (3.6–7.0) 7, 21.2 (9.0–38.9) 3, 12.5 (2.7–32.4) 4, 44.4 (13.7–78.8) 7, 21.2 (9.0–38.9)
Any type in
nonavalent vaccinec
626, 89.2 (86.6–91.4) 29, 87.9 (71.8–96.6) 23, 95.8 (78.9–99.9) 9, 100.0 (66.4–100.0) 32, 97.0 (84.2–99.9)
Any other IARC oncogenic
type not in nonavalent vaccinec
56, 8.0 (6.1–10.2) 1, 3.0 (0.1–15.8) 1, 4.2 (0.1–21.1) 0, 0.0 (0.0–33.6) 1, 3.0 (0.1–15.8)
Any type not classified
as oncogenic by IARCd
18, 2.6 (1.5–4.0) 0, 0.0 (0.0–10.6) 0, 0.0 (0.0–14.2) 0, 0.0 (0.0–33.6) 0, 0.0 (0.0–10.6)
HPV negativee 4, 0.6 (1.2–1.5) 1, 3.0 (0.1–15.8) 0, 0.0 (0.0–14.2) 0, 0.0 (0.0–33.6) 0, 0.0 (0.0–10.6)
Abbreviations: CI confidence interval, IARC International Agency for Research on Cancer
aMultiple HPV genotypes may be present for one biopsy, so column totals are greater than the number of biopsies and percentages do not sum to 100%
bA one-sided 97.5% confidence interval was calculated if there were zero observations
cOncogenic HPV genotypes in the nonavalent vaccine: 16, 18, 31, 33, 45, 52, 58
dHPV genotypes classified as oncogenic by IARC: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
eAfter retesting by WHO Global HPV Reference Laboratory
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from 847 women with invasive cancer from 2005 to
2015, before HPV vaccination (introduced in 2007)
would be expected to have had an impact [10]. Brother-
ton and colleagues found 0.8% with multiple HPV ge-
notypes and 7.1% samples with no HPV detected.
These differences probably result from the different
study populations, or from suboptimal DNA extrac-
tion at the deparaffinisation stage. We studied speci-
mens from 2014 to 2015, of which 91.4% were CIN3.
In small countries like Switzerland, the number of
women with invasive cervical cancer is too low for
this to be used as an outcome on its own. Between
the years 2010–2014, only 1271 cases (approximately
250 cases/year) of cervical cancer were registered with
the National Institute for Cancer Epidemiology and
Registration [30].
The top ranking HPV genotypes found in our study
are comparable to other European countries, although
the relative importance varies, depending on the speci-
men type and histological diagnosis [31–36]. In the
CIN3+ plus study, dominated by CIN3, the top five HPV
genotypes were HPV 16, 31, 33, 18 and 52. In Europe,
the top five ranking HPV genotypes in cytological and
tissue samples with high grade cervical precancerous le-
sions are HPV 16, 31, 33, 52 and 18 [37]. In invasive cer-
vical cancer, HPV genotypes 16, 18, 33, 45 and 31 are
the most frequent in cytological and tissue samples in
Europe [38]. In CIN3+ plus, HPV types 16, 18, 33, 45
and 56 were the most frequent in invasive cancers, but
there was only one biopsy with HPV 56 and none with
HPV 31. A meta-analysis of studies that examined exclu-
sively tissue samples with CIN3 worldwide, excluding Af-
rica, Western/Central Asia and South/Central America,
Table 3 Demographic characteristics of women in the CIN3 +
plus study group and age-adjusted Swiss National Cohort
CIN3+ plus study
groupa % or mean
(95% CI)
Swiss National
Cohortb % or mean
(95% CI)
p-value
Swiss-SEP Index 64.6 (63.8–65.4) 64.6 (64.5–64.7) 0.999
Canton of residence
Zurich 27.5 35.2 < 0.001
Geneva 25.2 19.9
Lucerne 15.5 18.6
Ticino 14.0 15.8
Basel-Land 9.7 6.0
Basel-City 6.1 4.4
Other & Unknown 2.1 0.0
Country of birth
Switzerland 49.0 60.0 0.001
Other 51.0 40.0
Nationality
Swiss 63.2 69.6 0.024
Other 36.8 30.4
Civil status
Single 48.9 45.5 < 0.001
Married 31.5 45.6
Divorced 10.7 6.1
Widowed 2.2 2.7
Other 6.7 0.0
Highest education level completed
≤ Compulsory
education
10.7 17.2 0.004
Upper secondary
level
51.9 43.3
Tertiary level 37.4 39.5
Abbreviations: CI confidence interval, SEP socioeconomic position
aNumbers of observations available: Swiss-SEP Index, 748; canton of residence,
767; country of birth, 241; nationality, 266; civil status, 270; highest education
level, 262
bNumbers of observations available: Swiss-SEP Index, 54769; canton of
residence, 54769; country of birth, 54711; nationality, 54769; civil status, 54768;
highest education level, 54769
Table 4 Factors associated with cervical cancer in CIN3+ plus
study group compared with the Swiss Health Survey
CIN3+ plus study
group n = 273
Swiss Health
Survey n = 3537
p-value
% or mean
(95% CI)
% or mean
(95% CI)
Number of sexual partners in the last 12 months
0 9.2 13.8 < 0.001a
1 74.0 78.8
≥ 2 15.4 6.8
Unknown 0.0 0.0
No answer 1.5 0.6
Age at first
sexual intercourseb
17.5 (17.2–17.9) 18.1 (17.9–18.2) 0.005
Reported hormonal
contraception use in
the last 12 monthsc
35.5 41.7 0.072
Current smoker 38.5 25.6 < 0.001
61.5 74.4
Have you ever had a Pap-test?d
Yes 89.0 81.5 0.002d
No 8.8 16.3
Unknown 1.1 0.5
No answer 1.1 0.0
Not asked 0.0 1.7
Abbreviations: CI confidence interval
aUnknown, no answer and not asked categories were not included in
statistical analysis
bThe number of observations for age at first sex was 270 for the CIN3 + plus
study group and 2914 for the Swiss Health Survey
cIncludes any intrauterine device for the Swiss Health Survey
dWomen were asked if they ever had a cervical cancer screening test before
the start of their current illness for the CIN3 + plus study
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found a ranking with a prevalence of HPV 16, 54.5%; HPV
33, 11.0%; HPV 52, 10.9%; HPV 58, 10.8%, HPV 31, 10.7%
[39]. Another meta-analysis examining women with inva-
sive cervical cancer worldwide, found that after HPV ge-
notypes 16 and 18, the most common genotypes (31, 33,
35, 45, 52 and 58) were the same in all continents, but
with differences in frequencies [3]. All but three (35, 42
and 51) of the top 10 ranking HPV genotypes in our study
are covered by the nonavalent vaccine.
Interpretation of the study
In the CIN3+ plus study, 61.8% of the biopsies were
positive for HPV genotypes 16 and/or 18 and could be
covered by the use of bivalent and quadrivalent vaccines.
Cross-protection against HPV genotypes 31, 33 and 45
provided by the bivalent or quadrivalent vaccine could
increase this estimate [40]. Up to 89.5% of biopsies ana-
lysed in this study contain HPV genotypes in the nona-
valent vaccine. The introduction of the nonavalent
vaccine in Switzerland could help prevent almost all
cases of CIN3+ if HPV vaccine uptake is adequate. In
2014–2016, the Swiss National Vaccination Coverage
Surveys calculated that 47.7% (95% CI 40.8–54.6%) of
16 year old girls had received two doses of a HPV vac-
cine. Cantons with school-based HPV programs had a
vaccination rate of 50.6% (95% CI 47.8–53.5%), whereas
cantons without a school-based program had a lower
rate of 37.2% (95% CI 34.1–40.3%) [41]. In countries like
Australia and England, more than 70% of young women
are vaccinated and steep reductions in genital warts and
HPV genotypes following use of the quadrivalent vaccine
in Australia suggest that this level of coverage provides
herd protection [42–44]. A study in one canton in
Switzerland with 70% HPV vaccine uptake also found a
reduction in these HPV genotypes in self-collected cervi-
covaginal samples in the youngest women participating
in cervical cancer screening 5 years after vaccine imple-
mentation [45], whilst a modelling study suggests that
the current average level of HPV vaccination in
Switzerland would also be sufficient to reduce the preva-
lence of HPV16 [46]. The data collected in the CIN3+ plus
study reflect HPV genotypes at the start of the cantonal
vaccination programmes. Only 10.3% of the women who
completed a patient questionnaire reported receiving a
HPV vaccine. Only one of 28 vaccinated women reported
having received HPV vaccine before the onset of sexual
intercourse and had a lesion with an HPV genotype that
was not in the vaccine that she received. Therefore, it is
highly likely that most of the vaccinated women were
already infected with HPV at the time of vaccination.
When compared with the Swiss general population,
women in the CIN3+ plus study group were more likely
to have been born abroad, be single and to have com-
pleted secondary level education. The higher proportion
of non-Swiss in our study population could be due to
low screening rates in this population before arrival to
Switzerland. These observed differences could also be
due to the canton of residence and reflect regional dif-
ferences. These results are partially consistent with a
study analysing data trends from 1992 to 2012 in
Switzerland that found that single women, those with a
lower education level and who were non-Swiss were less
likely to receive cervical cancer screening [47]. The
Swiss-SEP index was, however, similar in women in the
CIN3+ plus study and women in the Swiss general popu-
lation. This finding contrasts with the results of many
studies that have found that women with lower socio-
economic position are more likely to be diagnosed with
cervical cancer owing to lower levels of cytological
screening [48]. Possible explanations for our findings in
Switzerland are that the Swiss-SEP does not capture
relevant characteristics, that the proportion of Swiss
women below the poverty line is low (7.6%) [49], or that
the Swiss law requiring mandatory medical insurance
provides universal health coverage [50]. Women in the
CIN3+ plus study group were more likely to smoke and
had higher numbers of recent sexual partners than
women in the general population participating in the
SHS, but were less likely to use hormonal contraception.
Our results confirm the findings of other studies with
regard to smoking. Factors that are known or thought to
be associated with severe HPV-related disease include
number of lifetime partners, oral contraception use and
smoking [51]. Associations between hormone use and
cervical neoplasia are inconsistent [52].
Implications for public health and for future research
Monitoring of CIN3+ lesions, which are the clinical end-
points of interest, will be particularly important in coun-
tries with sub-optimal HPV vaccine coverage in which
vaccination herd effects are less likely. The data from
this study also suggest that introduction of the nonava-
lent HPV vaccine could help to prevent most CIN3+
cases in Switzerland if the uptake of HPV vaccination
can increase further. The introduction of a two-dose
vaccine schedule in 2012 for girls 11–14 years old and
for boys since 2015 [53] should help to increase HPV
vaccine coverage. In Switzerland, the cantonal cancer
registries record cervical cancers and most of them have
also collected data on CIN3 for several years. A new
Swiss law on cancer registration will make data collec-
tion about cervical cancer and CIN3 mandatory, so the
completeness of surveillance will increase.
The results of this study provide valuable information
for the establishment of a surveillance system for
HPV-associated cancers, especially cervical cancer, in
Switzerland and other countries with similar healthcare
systems [54]. Monitoring the changes in HPV genotype
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distribution will allow ongoing assessment of the impact
of HPV vaccination and about potential, but unlikely,
type replacement. HPV genotyping could be conducted
on FFPE biopsies as conducted in this study or could be
conducted on liquid- based cytology before histopath-
ology, although differences in HPV genotype distribution
may be obtained due to mixing of normal and lesion re-
gions [55]. The six cantons and 10 pathology institutes
that took part in the CIN3+ plus study could become a
sentinel surveillance system, rather than requiring all 26
Swiss cantons to take part, since the characteristics of
these cantons (Additional file 1: Table S5) and the distri-
bution of HPV vaccination uptake is broadly similar to
that of the whole country [41]. Statistical weighting of
data from sentinel cantons can be applied to achieve a
sample that represents the national distribution of char-
acteristics such as language region. Laboratories involved
in a surveillance programmes should participate in a
quality assurance programme for HPV genotyping.
Conclusions
In conclusion, we have documented the HPV type distri-
bution in high-grade cervical lesions at the beginning of
the Swiss cantonal HPV vaccination programmes.
Quadrivalent and bivalent vaccines cover around 62% of
CIN3+ lesions and 73% of invasive cervical cancers,
whereas the nonavalent vaccine would cover about 90%
of CIN3+ lesions and 97% of invasive cervical cancers.
Together, sentinel surveillance of HPV genotype distri-
bution in CIN3+ lesions, including information about
HPV vaccination, and of cervical cancer incidence in
cancer registries will provide the information needed to
monitor HPV vaccine effectiveness in Switzerland and to
plan the required public health activities.
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HPV Reference Laboratory. (DOCX 70 kb)
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